Tekla Capital Management as of March 31, 2014
Portfolio Holdings for Tekla Capital Management
Tekla Capital Management holds 61 positions in its portfolio as reported in the March 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Gilead Sciences (GILD) | 10.7 | $107M | 1.5M | 70.86 | |
| Celgene Corporation | 6.6 | $66M | 472k | 139.60 | |
| Regeneron Pharmaceuticals (REGN) | 6.3 | $63M | 211k | 300.28 | |
| Amgen (AMGN) | 5.5 | $55M | 450k | 123.34 | |
| Biogen Idec (BIIB) | 5.3 | $53M | 174k | 305.87 | |
| Alexion Pharmaceuticals | 5.1 | $51M | 336k | 152.13 | |
| Actavis | 4.2 | $42M | 206k | 205.85 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.5 | $35M | 500k | 70.72 | |
| Mylan | 3.2 | $32M | 652k | 48.83 | |
| Incyte Corporation (INCY) | 3.0 | $30M | 558k | 53.52 | |
| BioMarin Pharmaceutical (BMRN) | 2.9 | $29M | 421k | 68.21 | |
| Allergan | 2.7 | $27M | 216k | 124.10 | |
| Perrigo Company (PRGO) | 2.6 | $26M | 168k | 154.66 | |
| iShares NASDAQ Biotechnology Index (IBB) | 2.4 | $24M | 102k | 236.45 | |
| Shire | 2.3 | $23M | 154k | 148.53 | |
| Puma Biotechnology (PBYI) | 1.9 | $19M | 186k | 104.14 | |
| Aetna | 1.9 | $19M | 247k | 74.97 | |
| Cubist Pharmaceuticals | 1.7 | $17M | 227k | 73.15 | |
| Teva Pharmaceutical Industries (TEVA) | 1.6 | $17M | 312k | 52.84 | |
| Illumina (ILMN) | 1.5 | $15M | 104k | 148.66 | |
| Akorn | 1.5 | $15M | 699k | 22.00 | |
| Forest Laboratories | 1.4 | $14M | 147k | 92.27 | |
| McKesson Corporation (MCK) | 1.2 | $12M | 68k | 176.56 | |
| Catamaran | 1.0 | $10M | 231k | 44.76 | |
| Verastem | 1.0 | $9.9M | 919k | 10.79 | |
| Alere | 1.0 | $9.8M | 287k | 34.35 | |
| Celladon | 1.0 | $9.8M | 971k | 10.13 | |
| Heron Therapeutics (HRTX) | 1.0 | $9.7M | 697k | 13.91 | |
| Ironwood Pharmaceuticals (IRWD) | 0.9 | $9.5M | 768k | 12.32 | |
| Sagent Pharmaceuticals | 0.9 | $9.5M | 405k | 23.37 | |
| Impax Laboratories | 0.9 | $9.1M | 345k | 26.42 | |
| Endo International (ENDPQ) | 0.9 | $8.7M | 126k | 68.65 | |
| Alkermes (ALKS) | 0.9 | $8.6M | 195k | 44.09 | |
| Questcor Pharmaceuticals | 0.8 | $7.6M | 117k | 64.93 | |
| PerkinElmer (RVTY) | 0.8 | $7.5M | 166k | 45.06 | |
| Thermo Fisher Scientific (TMO) | 0.7 | $7.2M | 60k | 120.25 | |
| Accuray Incorporated (ARAY) | 0.7 | $7.0M | 732k | 9.60 | |
| Neurocrine Biosciences (NBIX) | 0.7 | $6.9M | 428k | 16.10 | |
| IDEXX Laboratories (IDXX) | 0.7 | $6.8M | 56k | 121.41 | |
| UnitedHealth (UNH) | 0.7 | $6.8M | 82k | 81.99 | |
| Intellipharmaceuticsintl Inc C | 0.6 | $6.2M | 1.4M | 4.40 | |
| BioDelivery Sciences International | 0.6 | $5.8M | 683k | 8.44 | |
| Pharmacyclics | 0.6 | $5.5M | 55k | 100.23 | |
| Acorda Therapeutics | 0.4 | $4.3M | 113k | 37.91 | |
| Infinity Pharmaceuticals (INFIQ) | 0.4 | $4.2M | 350k | 11.89 | |
| Alnylam Pharmaceuticals (ALNY) | 0.4 | $4.1M | 62k | 67.13 | |
| Molina Healthcare (MOH) | 0.4 | $3.9M | 105k | 37.56 | |
| Merrimack Pharmaceuticals In | 0.4 | $3.8M | 757k | 5.04 | |
| Centene Corporation (CNC) | 0.4 | $3.7M | 60k | 62.25 | |
| Aegerion Pharmaceuticals | 0.3 | $3.3M | 73k | 46.13 | |
| Clovis Oncology | 0.3 | $3.3M | 47k | 69.27 | |
| Mei Pharma | 0.3 | $2.7M | 244k | 11.13 | |
| NPS Pharmaceuticals | 0.2 | $2.5M | 83k | 29.93 | |
| Intermune Inc note 2.500% 9/1 | 0.2 | $2.3M | 1.8M | 1.29 | |
| Ptc Therapeutics I (PTCT) | 0.2 | $2.1M | 79k | 26.14 | |
| Bluebird Bio (BLUE) | 0.2 | $1.7M | 74k | 22.74 | |
| OncoGenex Pharmaceuticals | 0.1 | $1.3M | 113k | 11.76 | |
| Supernus Pharmaceuticals (SUPN) | 0.1 | $1.3M | 141k | 8.94 | |
| Auxilium Pharmaceuticals | 0.1 | $1.1M | 42k | 27.18 | |
| Sangamo Biosciences (SGMO) | 0.1 | $857k | 47k | 18.08 | |
| Macrogenics (MGNX) | 0.1 | $798k | 32k | 25.05 |
